公开(公告)号：US20070098720A1

公开(公告)日：2007-05-03

申请号：US11613409

申请日：2006-12-20

Applicant: David Thomas ,  Mark de Boer ,  Pieter Res ,  Peter Simons

Inventor： David Thomas ,  Mark de Boer ,  Pieter Res ,  Peter Simons

IPC: A61K39/395 ,  C07H21/04 ,  C12P21/06 ,  C12N5/06 ,  C07K16/28

CPC classification number: A61K39/39541 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2818 ,  C07K16/2878 ,  C07K2317/31 ,  A61K2300/00

Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.

Abstract translation: 公开了可以结合并刺激专业和非专业人抗原呈递细胞（“APC”）的激动剂抗CD40分子，包括单克隆抗体，增强CD40L对CD40阳性细胞的刺激作用和/或诱导表型成熟 的单核细胞来源的树突状细胞。 提供了几种这样的单克隆抗体，并且生产它们的细胞系已经保藏在美国典型培养物保藏中心。

公开(公告)号：US20050169923A1

公开(公告)日：2005-08-04

申请号：US11053536

申请日：2005-02-07

Applicant: Mark de Boer ,  Leah Conroy

Inventor： Mark de Boer ,  Leah Conroy

IPC: C12N15/02 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/573 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/16 ,  A61P7/06 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K14/705 ,  C07K16/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/06 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531 ,  C12N5/06

CPC classification number: C07K16/2878 ,  A61K38/00 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5156 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/70578 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026 ,  A61K2300/00

Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract translation: 提供了用于预防或治疗患者抗体介导的疾病的方法，所述方法包括施用能够结合位于人B细胞表面上的人CD40抗原的单克隆抗体，其中所述抗体与 CD40抗原阻止B细胞的生长或分化。 还提出了可用于这些方法的单克隆抗体和与这种单克隆抗体免疫反应的表位。

公开(公告)号：US6004552A

公开(公告)日：1999-12-21

申请号：US469015

申请日：1995-06-05

Applicant: Mark de Boer ,  Leah B Conroy

Inventor： Mark de Boer ,  Leah B Conroy

IPC: C12N15/02 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/573 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/16 ,  A61P7/06 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K14/705 ,  C07K16/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/06 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531

CPC classification number: C07K16/2878 ,  A61K39/395 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/70578 ,  C07K16/2827 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5156 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026

Abstract: Methods for preventing or treating an antibody-mediated diease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract translation: 提供了用于预防或治疗患者中抗体介导的死亡酶的方法，所述方法包括施用能够结合位于人B细胞表面上的人CD40抗原的单克隆抗体，其中所述抗体与 CD40抗原阻止B细胞的生长或分化。 还提出了可用于这些方法的单克隆抗体和与这种单克隆抗体免疫反应的表位。

公开(公告)号：US5747034A

公开(公告)日：1998-05-05

申请号：US200716

申请日：1994-02-18

Applicant: Mark de Boer ,  Leah B. Conroy

Inventor： Mark de Boer ,  Leah B. Conroy

IPC: C12N15/02 ,  A61K31/436 ,  A61K31/445 ,  A61K31/56 ,  A61K31/57 ,  A61K31/70 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P19/02 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  C07H21/04 ,  C07K14/705 ,  C07K16/28 ,  C07K16/42 ,  C12N5/00 ,  C12N5/10 ,  C12P21/08 ,  C12R1/91 ,  C07K16/18 ,  C12N5/12

CPC classification number: C07K16/2827 ,  A61K39/395 ,  C07K14/70532 ,  C07K16/2878 ,  A61K2039/505 ,  A61K38/00 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2319/30 ,  C12N2799/026 ,  Y10S530/809

Abstract: Anti-B7-1 antibodies or other B7-1 ligands may be used to prevent or treat a T-cell-mediated immune system disease in a patient or to induce antigen-specific tolerance. The anti-B7-1 antibodies may be used to cause T cell anergy, treat allograft transplant rejection, treat graft versus host disease, and prevent or treat rheumatoid arthritis. An immunosuppressive agent is co-administered with the antibody.

Abstract translation: 抗B7-1抗体或其他B7-1配体可用于预防或治疗患者中T细胞介导的免疫系统疾病或诱导抗原特异性耐受。 抗B7-1抗体可用于引起T细胞无反应性，治疗同种异体移植排斥反应，治疗移植物抗宿主病，以及预防或治疗类风湿性关节炎。 免疫抑制剂与抗体共同施用。

公开(公告)号：US07361345B2

公开(公告)日：2008-04-22

申请号：US11053536

申请日：2005-02-07

Applicant: Mark de Boer ,  Leah B. Conroy

Inventor： Mark de Boer ,  Leah B. Conroy

IPC: A61K39/395 ,  C07K16/28 ,  C12N5/12

CPC classification number: C07K16/2878 ,  A61K38/00 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5156 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/70578 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026 ,  A61K2300/00

Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract translation: 提供了用于预防或治疗患者抗体介导的疾病的方法，所述方法包括施用能够结合位于人B细胞表面上的人CD40抗原的单克隆抗体，其中所述抗体与 CD40抗原阻止B细胞的生长或分化。 还提出了可用于这些方法的单克隆抗体和与这种单克隆抗体免疫反应的表位。

公开(公告)号：US06899879B2

公开(公告)日：2005-05-31

申请号：US09954764

申请日：2001-09-18

Applicant: Mark de Boer ,  Leah B Conroy

Inventor： Mark de Boer ,  Leah B Conroy

IPC: C12N15/02 ,  A61K31/4353 ,  A61K31/436 ,  A61K31/573 ,  A61K38/00 ,  A61K39/395 ,  A61K45/00 ,  A61P1/16 ,  A61P7/06 ,  A61P29/00 ,  A61P37/02 ,  A61P37/06 ,  A61P37/08 ,  A61P43/00 ,  C07K14/705 ,  C07K16/00 ,  C07K16/28 ,  C12N5/10 ,  C12N15/06 ,  C12N15/09 ,  C12P21/02 ,  C12P21/08 ,  G01N33/53 ,  G01N33/531

CPC classification number: C07K16/2878 ,  A61K38/00 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5156 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/70578 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026 ,  A61K2300/00

Abstract: Methods for preventing or treating an IgE-mediated allergic disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract translation: 提供了用于预防或治疗患者中IgE介导的过敏性疾病的方法，所述方法包括施用能够结合位于人B细胞表面上的人CD40抗原的单克隆抗体，其中所述抗体与 CD40抗原阻止B细胞的生长或分化。 还提出了可用于这些方法的单克隆抗体和与这种单克隆抗体免疫反应的表位。

公开(公告)号：US07820807B2

公开(公告)日：2010-10-26

申请号：US12420481

申请日：2009-04-08

Applicant: David Thomas ,  Mark De Boer ,  Pieter C. J. M. Res ,  Peter J. Simons

Inventor： David Thomas ,  Mark De Boer ,  Pieter C. J. M. Res ,  Peter J. Simons

IPC: C12N15/13 ,  C12N15/12 ,  C12N5/10

CPC classification number: A61K39/39541 ,  A61K38/00 ,  A61K2039/505 ,  C07K16/2818 ,  C07K16/2878 ,  C07K2317/31 ,  A61K2300/00

Abstract: Disclosed are agonist anti-CD40 molecules, including monoclonal antibodies, which can bind to and stimulate professional and non-professional human antigen-presenting cells (“APCs”), enhance the stimulatory effect of CD40L on CD40 positive cells and/or induce phenotypical maturation of monocyte derived dendritic cells. Several such monoclonal antibodies are provided, and cell lines producing them have been deposited at the American Type Culture Collection.

Abstract translation: 公开了可以结合并刺激专业和非专业人抗原呈递细胞（“APC”）的激动剂抗CD40分子，包括单克隆抗体，增强CD40L对CD40阳性细胞的刺激作用和/或诱导表型成熟 的单核细胞来源的树突状细胞。 提供了几种这样的单克隆抗体，并且生产它们的细胞系已经保藏在美国典型培养物保藏中心。

公开(公告)号：US07790166B2

公开(公告)日：2010-09-07

申请号：US12049850

申请日：2008-03-17

Applicant: Mark de Boer ,  Leah B. Conroy

Inventor： Mark de Boer ,  Leah B. Conroy

IPC: A61K39/395 ,  C07K16/28 ,  C12N5/12 ,  A61K39/44

CPC classification number: C07K16/2878 ,  A61K38/00 ,  A61K39/395 ,  A61K2039/505 ,  A61K2039/5154 ,  A61K2039/5156 ,  C07K14/705 ,  C07K14/70532 ,  C07K14/70578 ,  C07K16/2827 ,  C07K2317/24 ,  C07K2317/73 ,  C07K2317/74 ,  C07K2319/00 ,  C07K2319/30 ,  C12N2799/026 ,  A61K2300/00

Abstract: Methods for preventing or treating an antibody-mediated disease in a patient are presented, the methods comprising administration of a monoclonal antibody capable of binding to a human CD40 antigen located on the surface of a human B cell, wherein the binding of the antibody to the CD40 antigen prevents the growth or differentiation of the B cell. Monoclonal antibodies useful in these methods, and epitopes immunoreactive with such monoclonal antibodies are also presented.

Abstract translation: 提供了用于预防或治疗患者抗体介导的疾病的方法，所述方法包括施用能够结合位于人B细胞表面上的人CD40抗原的单克隆抗体，其中所述抗体与 CD40抗原阻止B细胞的生长或分化。 还提出了可用于这些方法的单克隆抗体和与这种单克隆抗体免疫反应的表位。

公开(公告)号：US06893553B1

公开(公告)日：2005-05-17

申请号：US09889967

申请日：2000-01-20

Applicant: Satoshi Abe ,  Yasuhito Takahashi ,  Akira Hino ,  Mark De Boer

Inventor： Satoshi Abe ,  Yasuhito Takahashi ,  Akira Hino ,  Mark De Boer

IPC: B01J21/12 ,  B01J23/85 ,  B01J23/88 ,  B01J23/887 ,  B01J35/10 ,  C10G45/08 ,  C10G49/04 ,  C10G47/00 ,  B01J23/04 ,  C10G45/04 ,  C10G45/60

CPC classification number: B01J35/1019 ,  B01J21/12 ,  B01J23/85 ,  B01J23/88 ,  B01J23/8872 ,  B01J35/10 ,  B01J35/1042 ,  B01J35/108 ,  C10G49/04

Abstract: The invention pertains to a hydroprocessing catalyst comprising a Group VIB hydrogenation metal component, a non-noble Group VIII hydrogenation metal component, an alkali metal component, and silica. The catalyst has a specific surface area, total pore volume and pore size distribution. The invention also pertains to the use of this catalyst in hydroprocessing of heavy hydrocarbon feedstocks, e.g, in an ebullated bed process.

Abstract translation: 本发明涉及包含VIB族氢化金属组分，非贵金属VIII氢化金属组分，碱金属组分和二氧化硅的加氢处理催化剂。 催化剂具有比表面积，总孔体积和孔径分布。 本发明还涉及这种催化剂在重烃原料的加氢处理中的用途，例如在沸腾床方法中。

公开(公告)号：US06346248B1

公开(公告)日：2002-02-12

申请号：US09373474

申请日：1999-08-12

Applicant: Mark De Boer ,  G. C. De Gast

Inventor： Mark De Boer ,  G. C. De Gast

IPC: A61K39395

CPC classification number: A61K47/6849 ,  A61K47/6825

Abstract: A method for treating autoimmune diseases comprising administering to a patient in need of such treatment a therapeutically effective amount of an immunotoxin comprising an anti-human CD86 monoclonal antibody IG10H6D10 as deposited in the ECACC collection under No. 95060210 or a humanized antibody, a single-chain antibody or fragments and specificity of said monoclonal antibody, coupled to a toxin or active fragments thereof wherein the binding of the immunotoxin to CD86 results in the killing of the CD86 expressing cell.

Abstract translation: 一种治疗自身免疫性疾病的方法，包括向需要这种治疗的患者施用治疗有效量的免疫毒素，其包含沉积在ECACC集合号95060210中的抗人CD86单克隆抗体IG10H6D10或人源化抗体， 链抗体或所述单克隆抗体的片段和特异性，其与毒素或其活性片段偶联，其中免疫毒素与CD86的结合导致CD86表达细胞的杀死。